Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy Volunteers

A Phase 1, Open Label, Fixed-Sequence Study To Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy Volunteers

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01204112

Enrollment

Registered

2010-09-17

Start date

2010-09-30

Completion date

2010-10-31

Last updated

2010-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Drug-Drug Interaction, Tasocitinib (CP-690, 550), Rifampin, Healthy Volunteers

Brief summary

The current study is designed to estimate the effect of rifampin (600 mg orally every 24 hours for 7 days) on pharmacokinetics of single 30 mg dose (CP-690,550) in normal healthy volunteers

Interventions

DRUGTasocitinib (CP-690,550) plus Rifampin

Period 1, Day 1: Tasocitinib (CP-690,550) 30 mg (single oral dose) as six 5 mg tablets Period 2, Day 1-7: Rifampin 600 mg (single oral dose) q24h Period 2, Day 8: Tasocitinib (CP-690,550) 30 mg (single oral dose) as six 5 mg tablets Period 2, Day 9: No treatment (discharge)

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy male and/or female subjects (of non-childbearing potential)

Exclusion criteria

* Clinically significant disease or condition * Recent serious infection

Design outcomes

Primary

Measure	Time frame
AUCinf of tasocitinib (CP-690,550)	9 days
Cmax of tasocitinib (CP-690,550)	9 days

Secondary

Measure	Time frame
AUClast, Tmax, t1/2 of tasocitinib (CP-690,550)	9 days
Safety: clinical laboratory abnormalities, AE reporting, and vital signs (blood pressure/pulse rate).	9 days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026